Hangzhou Diagens Biotechnology Co., Ltd./ADR
HGZDYNext catalyst
Picankibart
Rheumatoid Arthritis
Get an email about HGZDY's next catalysts
Track Hangzhou Diagens Biotechnology Co., Ltd./ADR (HGZDY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
FDA PDUFA Date Zemprocitinib
For Rheumatoid Arthritis. NDA accepted. AI-extracted from: Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zempr
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Picankibart | Phase 3 | Psoriatic Arthritis | - | - |
IBI112 | Phase 3 | Psoriasis | - | - |
Frequently asked questions
What is in Hangzhou Diagens Biotechnology Co., Ltd./ADR's drug pipeline?β
CatalystAlert tracks 2 drug candidates in Hangzhou Diagens Biotechnology Co., Ltd./ADR's (HGZDY) pipeline across Phase 3. Its lead program is Picankibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hangzhou Diagens Biotechnology Co., Ltd./ADR's next FDA catalyst?β
Hangzhou Diagens Biotechnology Co., Ltd./ADR's (HGZDY) next tracked catalyst is a PDUFA date expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HGZDY biotech catalysts?β
Add HGZDY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hangzhou Diagens Biotechnology Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
